SWTX 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分較低，若以價值投資為目標，已經有長期投資部位可能需陸續減碼
SWTX 近期報酬表現
0.16%
Springworks therapeutics inc
-0.77%
同產業平均
0.12%
S&P500
與 SWTX 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
LXEO | Lexeo therapeutics inc | - | 3 分 | 4 分 | 3 分 | 1 分 | |
MLYS | Mineralys therapeutics inc | - | 4 分 | 4 分 | 2 分 | 1 分 | |
IOVA | Iovance biotherapeutics inc | 3 分 | 2 分 | 2 分 | 2 分 | 1 分 | |
PTCT | Ptc therapeutics inc | 2 分 | 5 分 | 2 分 | 3 分 | 1 分 | |
NRIX | Nurix therapeutics inc | 4 分 | 5 分 | 3 分 | 3 分 | 1 分 |
- LXEO Lexeo therapeutics inc價值 -趨勢 3 分波段 4 分籌碼 3 分股利 1 分查看更多
SWTX 公司資訊
SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer. OGSIVEO (nirogacestat) is the Company's Food and Drug Administration (FDA)-approved therapy. OGSIVEO (nirogacestat) is approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment. The Company also has a diversified targeted therapy pipeline spanning solid tumors and hematological cancers, with programs ranging from preclinical development through advanced clinical trials. Its ongoing developments include Nirogacestat for treatment of ovarian granulosa cell tumors, Nirogacestat in combination with B-cell maturation antigen (BCMA)-targeted agents, Mirdametinib Phase 2b ReNeu trial in NF1-PN and Brimarafenib (BGB-3245). The Company's early-stage pipeline includes SW-682, an investigational oral, small molecule TEA Domain (TEAD), inhibitor that is evaluated in Hippo-mutant solid tumors.